HBV感染肾小管细胞机制的研究进展

李迎娟; 冯国和

doi:10.3969/j.issn.1001-5256.2021.03.036

HBV感染肾小管细胞机制的研究进展

DOI: 10.3969/j.issn.1001-5256.2021.03.036

李迎娟,
冯国和^,

中国医科大学附属盛京医院感染科，沈阳110000

利益冲突声明: 所有作者均声明不存在利益冲突。

作者贡献声明：李迎娟负责资料分析，撰写论文，修改论文；冯国和负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

作者简介:
李迎娟(1995—)，女，主要从事慢性HBV感染方面研究

通信作者:
冯国和，fenggh@sj-hospital.org

中图分类号: R512.62;R57
计量
- 文章访问数: 371
- HTML全文浏览量: 104
- PDF下载量: 57
- 被引次数: 0
出版历程
- 收稿日期: 2020-09-06
- 录用日期: 2020-10-30
- 出版日期: 2021-03-20

Research advances in infection of renal tubular cells by hepatitis B virus

Yingjuan LI,
Guohe FENG^,

Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang 110000, China

摘要

摘要: 肾脏具备HBV感染肝细胞的关键因素，HBV相关肾小球肾炎(HBV-GN)的发病机制尚未完全明确，近年来HBV直接损伤肾小管的机制越来越受到重视。HBV可以通过调节细胞周期、激活NF-κB等相关信号转导通路诱导肾小管细胞凋亡，导致HBV-GN进展。目前在临床上尚无作用靶点位于肾脏治疗HBV-GN的药物。将HBV感染细胞的关键因素和HBV损伤肾小管细胞研究进展总结如下，阐述HBV直接感染肾小管细胞的可能机制，为HBV-GN的治疗提供新思路。
- 乙型肝炎病毒 /
- 肾小管 /
- 感染
Abstract: The kidney plays a key role in hepatitis B virus (HBV) infection of liver cells. The pathogenesis of HBV-associated glomerulonephritis (HBV-GN) remains unclear, and the mechanism of HBV directly causing the injury of renal tubules has been taken seriously in recent years. HBV can induce the apoptosis of renal tubular cells by regulating cell cycle and activating related signaling pathways including NF-κB and thus lead to the progression of HBV-GN. At present, there are still no drugs targeting the kidney in the treatment of HBV-GN. This article summarizes the research advances in the key factors for HBV infection of cells and the injury of renal tubular cells caused by HBV and elaborates on the possible mechanism of direct infection of renal tubular cells by HBV, so as to provide new ideas for the treatment of HBV-GN.
- Hepatitis B Virus /
- Kidney Tubules /
- Infection

HTML全文

参考文献(44)

[1]	Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6
[2]	AMET S, BRONOWICKI JP, THABUT D, et al. Prevalence of renal abnormalities in chronic HBV infection: The HARPE study[J]. Liver Int, 2015, 35(1): 148-155. DOI: 10.1111/liv.12480
[3]	XU MD F, WANG MD C, SHI MD X, et al. Resolution of HBV infection occurs sooner than recovery of renal disease in adult serum HBsAg-negative HBV-associated glomerulonephritis[J]. J Med Virol, 2018, 90(9): 1503-1507. DOI: 10.1002/jmv.25211
[4]	VERRIER ER, COLPITTS CC, BACH C, et al. A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses[J]. Hepatology, 2016, 63(1): 35-48. DOI: 10.1002/hep.28013
[5]	MITRA B, THAPA RJ, GUO H, et al. Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B[J]. Antiviral Res, 2018, 158: 185-198. DOI: 10.1016/j.antiviral.2018.08.014
[6]	YANG F, WU L, XU W, et al. Diverse effects of the NTCP p. Ser267Phe Variant on disease progression during chronic HBV infection and on HBV preS1 variability[J]. Front Cell Infect Microbiol, 2019, 9: 18. DOI: 10.3389/fcimb.2019.00018
[7]	MEREDITH LW, HU K, CHENG X, et al. Lentiviral hepatitis B pseudotype entry requires sodium taurocholate co-transporting polypeptide and additional hepatocyte-specific factors[J]. J Gen Virol, 2016, 97(1): 121-127. DOI: 10.1099/jgv.0.000317
[8]	KO HL, LAM TH, NG H, et al. Identification of Slug and SOX7 as transcriptional repressors binding to the hepatitis B virus core promoter[J]. J Hepatol, 2017.[Online ahead of print]
[9]	FERDEK PE, JAKUBOWSKA MA, GERASIMENKO JV, et al. Bile acids induce necrosis in pancreatic stellate cells dependent on calcium entry and sodium-driven bile uptake[J]. J Physiol, 2016, 594(21): 6147-6164. DOI: 10.1113/JP272774
[10]	LAU HH, NG N, LOO L, et al. The molecular functions of hepatocyte nuclear factors - In and beyond the liver[J]. J Hepatol, 2018, 68(5): 1033-1048. DOI: 10.1016/j.jhep.2017.11.026
[11]	YANG X, CAI W, SUN X, et al. Defined host factors support HBV infection in non-hepatic 293T cells[J]. J Cell Mol Med, 2020, 24(4): 2507-2518. DOI: 10.1111/jcmm.14944
[12]	HERRSCHER C, PASTOR F, BURLAUD-GAILLARD J, et al. Hepatitis B virus entry into HepG2-NTCP cells requires clathrin-mediated endocytosis[J]. Cell Microbiol, 2020, 22(8): e13205.
[13]	IWAMOTO M, SASO W, SUGIYAMA R, et al. Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization[J]. Proc Natl Acad Sci U S A, 2019, 116(17): 8487-8492. DOI: 10.1073/pnas.1811064116
[14]	OCHI M, OTSUKA M, MARUYAMA R, et al. HBx increases EGFR expression by inhibiting miR129-5p function[J]. Biochem Biophys Res Commun, 2020, 529(2): 198-203. DOI: 10.1016/j.bbrc.2020.06.018
[15]	GAN CJ, LI WF, LI CN, et al. EGF receptor inhibitors comprehensively suppress hepatitis B virus by downregulation of STAT3 phosphorylation[J]. Biochem Biophys Rep, 2020, 22: 100763. http://www.sciencedirect.com/science/article/pii/S2405580820300728
[16]	LI H, SHAO F, QIAN B, et al. Upregulation of HER2 in tubular epithelial cell drives fibroblast activation and renal fibrosis[J]. Kidney Int, 2019, 96(3): 674-688. DOI: 10.1016/j.kint.2019.04.012
[17]	HERRSCHER C, ROINGEARD P, BLANCHARD E. Hepatitis B virus entry into cells[J]. Cells-Basel, 2020, 9(6): 1486. DOI: 10.3390/cells9061486
[18]	IWAMOTO M, SASO W, NISHIOKA K, et al. The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network[J]. J Biol Chem, 2020, 295(3): 800-807. DOI: 10.1016/S0021-9258(17)49936-4
[19]	HU Q, ZHANG F, DUAN L, et al. E-cadherin plays a role in hepatitis B virus entry through affecting glycosylated sodium-taurocholate cotransporting polypeptide distribution[J]. Front Cell Infect Microbiol, 2020, 10: 74. DOI: 10.3389/fcimb.2020.00074
[20]	WANG X, WANG L, ZHU N, et al. Hepatitis B virus X protein modulates renal tubular epithelial cell-induced T-cell and macrophage responses[J]. Immunol Cell Biol, 2016, 94(3): 266-273. DOI: 10.1038/icb.2015.85
[21]	HOCHANE M, RAISON D, COQUARD C, et al. Parathyroid hormone-related protein modulates inflammation in mouse mesangial cells and blunts apoptosis by enhancing COX-2 expression[J]. Am J Physiol Cell Physiol, 2018, 314(2): C242-C253. DOI: 10.1152/ajpcell.00018.2017
[22]	MASOLA V, CARRARO A, GRANATA S, et al. In vitro effects of interleukin (IL)-1 beta inhibition on the epithelial-to-mesenchymal transition (EMT) of renal tubular and hepatic stellate cells[J]. J Transl Med, 2019, 17(1): 12. DOI: 10.1186/s12967-019-1770-1
[23]	WANG L, YE Z, LIANG H, et al. The combination of tacrolimus and entecavir improves the remission of HBV-associated glomerulonephritis without enhancing viral replication[J]. Am J Transl Res, 2016, 8(3): 1593-1600. http://europepmc.org/abstract/MED/26807867
[24]	ALLWEISS L, DANDRI M. The role of cccDNA in HBV maintenance[J]. Viruses, 2017, 9(6): 156. DOI: 10.3390/v9060156
[25]	LEVRERO M, ZUCMAN-ROSSI J. Mechanisms of HBV-induced hepatocellular carcinoma[J]. J Hepatol, 2016, 64(1 Suppl): S84-S101. http://smartsearch.nstl.gov.cn/paper_detail.html?id=7e744aa37429a3f8dc9f486b56f9e28c
[26]	PRESCOTT NA, BRAM Y, SCHWARTZ RE, et al. Targeting hepatitis B virus covalently closed circular DNA and hepatitis B virus x protein: Recent advances and new approaches[J]. ACS Infect Dis, 2019, 5(10): 1657-1667. DOI: 10.1021/acsinfecdis.9b00249
[27]	LIANG DY, SHA S, YI Q, et al. Hepatitis B X protein upregulates decoy receptor 3 expression via the PI3K/NF-κB pathway[J]. Cell Signal, 2019, 62: 109346. DOI: 10.1016/j.cellsig.2019.109346
[28]	WU A, CHEN H, XU C, et al. miR-203a is involved in HBx-induced inflammation by targeting Rap1a[J]. Exp Cell Res, 2016, 349(1): 191-197. DOI: 10.1016/j.yexcr.2016.10.016
[29]	HAN W, LUO M, HE M, et al. HBx gene transfection affects the cycle of primary renal tubular epithelial cells through regulating cyclin expression[J]. Mol Med Rep, 2018, 18(2): 1947-1954. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072163/
[30]	LI M, HU L, ZHU F, et al. Hepatitis B virus X protein promotes renal epithelial-mesenchymal transition in human renal proximal tubule epithelial cells through the activation of NF-κB[J]. Int J Mol Med, 2016, 38(2): 513-520. DOI: 10.3892/ijmm.2016.2637
[31]	YANG Y, WANG X, ZHANG Y, et al. Hepatitis B virus X protein and proinflammatory cytokines synergize to enhance TRAIL-induced apoptosis of renal tubular cells by upregulation of DR4[J]. Int J Biochem Cell Biol, 2018, 97: 62-72. DOI: 10.1016/j.biocel.2018.02.006
[32]	LI J, BAO L, ZHA D, et al. Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways[J]. Int Immunopharmacol, 2018, 55: 9-19. DOI: 10.1016/j.intimp.2017.11.040
[33]	FENG Y, CUI Y, GAO JL, et al. Resveratrol attenuates neuronal autophagy and inflammatory injury by inhibiting the TLR4/NF-κB signaling pathway in experimental traumatic brain injury[J]. Int J Mol Med, 2016, 37(4): 921-930. DOI: 10.3892/ijmm.2016.2495
[34]	YANG YT, WANG X, ZHANG YY, et al. The histone demethylase LSD1 promotes renal inflammation by mediating TLR4 signaling in hepatitis B virus-associated glomerulonephritis[J]. Cell Death Dis, 2019, 10(4): 278. DOI: 10.1038/s41419-019-1514-4
[35]	CHEN J, LI D, LUO E. Telbivudine antagonizes TLR4 to inhibit the epithelial-to-mesenchymal transition in human proximal tubular epithelial cells in vitro[J]. Int Immunopharmacol, 2019, 74: 105683. DOI: 10.1016/j.intimp.2019.105683
[36]	HE P, ZHANG B, LIU D, et al. Hepatitis B virus x protein modulates apoptosis in NRK-52E Cells and activates Fas/FasL through the MLK3-MKK7-JNK3 signaling pathway[J]. Cell Physiol Biochem, 2016, 39(4): 1433-1443. DOI: 10.1159/000447846
[37]	FU B, JI Y, HU S, et al. Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: A meta-analysis[J]. PLoS One, 2020, 15(1): e0227532. DOI: 10.1371/journal.pone.0227532
[38]	WANG WN, WU MY, MA FZ, et al. Meta-analysis of the efficacy and safety of nucleotide/nucleoside analog monotherapy for hepatitis B virus-associated glomerulonephritis[J]. Clin Nephrol, 2016, 85(1): 21-29. http://europepmc.org/abstract/med/26636326
[39]	JIANG W, LIU T, DONG H, et al. Relationship between serum DNA replication, clinicopathological characteristics and prognosis of hepatitis B virus-associated glomerulonephritis with severe proteinuria by lamivudine plus adefovir dipivoxil combination therapy[J]. Biomed Environ Sci, 2015, 28(3): 206-213. http://d.wanfangdata.com.cn/periodical/bes201503005
[40]	KAMIMURA H, SETSU T, KIMURA N, et al. Renal impairment in chronic hepatitis B: A review[J]. Diseases, 2018, 6(2): 52. DOI: 10.3390/diseases6020052
[41]	SUN LJ, SHAN JP, CUI RL, et al. Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: A clinical review of 38 cases[J]. Int Urol Nephrol, 2017, 49(6): 1049-1056. DOI: 10.1007/s11255-017-1563-5
[42]	MAHAJAN V, D'CRUZ S, NADA R, et al. Successful use of entecavir in hepatitis B-associated membranous nephropathy[J]. J Trop Pediatr, 2018, 64(3): 249-252. DOI: 10.1093/tropej/fmx058
[43]	KATAOKA H, MOCHIZUKI T, AKIHISA T, et al. Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report[J]. Medicine (Baltimore), 2019, 98(2): e14014. DOI: 10.1097/MD.0000000000014014
[44]	FANG J, LI W, PENG X, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: A retrospective analysis[J]. Int Urol Nephrol, 2017, 49(3): 475-482. DOI: 10.1007/s11255-016-1487-5